Epigral Ltd Hits Intraday High with Strong 7.8% Surge on 3 Feb 2026

Intraday Trading Highlights

Epigral Ltd opened the trading session with a gap up of 3.49%, signalling early bullish sentiment among market participants. The stock continued to gain momentum throughout the day, eventually touching an intraday high of Rs 1001.65, representing a 7.98% rise. This intraday peak was accompanied by a day change of 7.8%, significantly outperforming the Specialty Chemicals sector, which gained 4.09% on the same day.

Notably, Epigral’s performance today also surpassed the Sensex’s gain of 3.02%, with the stock rising by 7.15% compared to the benchmark index. This marks a reversal after two consecutive days of decline, indicating a shift in trading dynamics for the company’s shares.

Market Context and Sector Activity

The broader market experienced mixed movements on 3 Feb 2026. The Sensex opened sharply higher by 3,656.74 points but lost momentum, retreating by 1,189.82 points to close at 84,133.38, down 3.02% on the day. Despite this, the index remains close to its 52-week high of 86,159.02, just 2.41% away. The Sensex is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, suggesting some underlying support in the medium term.

Within this environment, mega-cap stocks led the market gains, while the Chemicals sector, to which Epigral belongs, posted a solid 4.09% increase. Epigral’s outperformance relative to both its sector and the Sensex highlights its distinct trading activity amid broader market fluctuations.

Technical and Trend Analysis

Despite today’s strong rally, Epigral continues to trade below its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This indicates that while the stock has shown a positive intraday reversal, it remains in a longer-term downtrend. The recent gain after two days of consecutive falls suggests a short-term correction or consolidation phase rather than a sustained trend reversal.

Over various time frames, Epigral’s performance has lagged the Sensex considerably. The stock’s one-week return stands at -6.05% against the Sensex’s 2.78%, and its one-month performance is down 20.35% compared to the Sensex’s marginal decline of 1.90%. The three-month and one-year returns show even wider underperformance, with Epigral down 41.46% and 44.78% respectively, while the Sensex posted gains of 0.18% and 9.00% over the same periods.

Mojo Score and Rating Update

Epigral Ltd currently holds a Mojo Score of 31.0, categorised under a 'Sell' grade as of 26 Dec 2025, an upgrade from its previous 'Strong Sell' rating. The Market Cap Grade stands at 3, reflecting its mid-tier market capitalisation within the Specialty Chemicals sector. These ratings provide a quantitative assessment of the stock’s quality and market standing, incorporating multiple financial and market parameters.

Comparative Performance and Longer-Term Trends

Year-to-date, Epigral has declined by 18.48%, underperforming the Sensex’s modest fall of 1.28%. Over three and five years, the stock’s returns have been flat or negative, contrasting sharply with the Sensex’s robust gains of 38.28% and 67.41% respectively. Over a decade, Epigral’s performance remains unchanged, while the Sensex has surged by 247.32%, underscoring the stock’s relative underperformance in the long term.

These figures highlight the challenges Epigral has faced in maintaining upward momentum over extended periods, despite occasional intraday rallies such as the one witnessed today.

Summary of Trading Action

Epigral Ltd’s strong intraday performance on 3 Feb 2026 was characterised by a significant price surge, outperforming both its sector and the broader market indices. The stock’s gap up opening and subsequent rise to Rs 1001.65 reflect active buying interest during the session. However, the stock remains below key moving averages, indicating that the recent gains are part of a short-term correction rather than a sustained upward trend.

While the Chemicals sector showed healthy gains, Epigral’s outperformance was notable given the broader market’s retreat from its opening highs. The stock’s Mojo Score and rating upgrade to 'Sell' from 'Strong Sell' suggest some improvement in its underlying metrics, though it continues to face challenges relative to the benchmark Sensex and sector peers.

Investors and market watchers will likely continue to monitor Epigral’s price action and volume trends in the coming sessions to assess whether this intraday strength can be sustained or if it remains a temporary rebound within a longer-term downtrend.

Unlock special upgrade rates for a limited period. Start Saving Now →